| CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response NF Kuhn, TJ Purdon, DG van Leeuwen, AV Lopez, KJ Curran, ... Cancer cell 35 (3), 473-488. e6, 2019 | 225 | 2019 |
| Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaAddressing BCMA … C Fernández de Larrea, M Staehr, AV Lopez, KY Ng, Y Chen, ... Blood cancer discovery 1 (2), 146-154, 2020 | 170* | 2020 |
| Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response X Li, AF Daniyan, AV Lopez, TJ Purdon, RJ Brentjens Leukemia 35 (2), 506-521, 2021 | 49 | 2021 |
| Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T CellsCostimulation-Driven Dysfunction of CAR T Cells D Wijewarnasuriya, C Bebernitz, AV Lopez, S Rafiq, RJ Brentjens Cancer immunology research 8 (6), 732-742, 2020 | 29 | 2020 |
| CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function NF Kuhn, AV Lopez, X Li, W Cai, AF Daniyan, RJ Brentjens Nature communications 11 (1), 1-10, 2020 | 28 | 2020 |
| Optimization of T-cell Receptor–Modified T Cells for Cancer TherapyIL18-Secreting TCR-Modified T Cells Augment Cancer Therapy DJ Drakes, S Rafiq, TJ Purdon, AV Lopez, SS Chandran, CA Klebanoff, ... Cancer immunology research 8 (6), 743-755, 2020 | 27 | 2020 |
| Optimal dual-targeted CAR construct simultaneously targeting Bcma and GPRC5D prevents Bcma-escape driven relapse in multiple myeloma CF De Larrea, M Staehr, A Lopez, Y Chen, TJ Purdon, KY Ng, H Wendel, ... Blood 134, 136, 2019 | 25 | 2019 |
| Augmenting CAR T Cell Mediated Anti-Tumor Efficacy through Genetic Modification to Secrete a Novel Cytokine IL-36 gamma X Li, A Daniyan, A Lopez, T Purdon, R Brentjens MOLECULAR THERAPY 27 (4), 432-433, 2019 | 1 | 2019 |
